USD
$0.00
(0.00%
)At Close (As of Nov 26, 2025)
$3.60M
Market Cap
0.0063
P/E Ratio
350.73
EPS
$24.36
52 Week High
$1.75
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $506K |
| Total Revenue | $1.3M |
| Cost Of Revenue | $800K |
| Costof Goods And Services Sold | $800K |
| Operating Income | -$7.3M |
| Selling General And Administrative | $4.3M |
| Research And Development | $1.8M |
| Operating Expenses | $7.8M |
| Investment Income Net | - |
| Net Interest Income | $391K |
| Interest Income | $421K |
| Interest Expense | $30K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $482K |
| Income Before Tax | -$7.5M |
| Income Tax Expense | -$14K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$7.5M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$7.5M |
| Ebitda | -$7M |
| Net Income | -$6.3M |
| Field | Value (USD) |
|---|---|
| Total Assets | $10M |
| Total Current Assets | $7.5M |
| Cash And Cash Equivalents At Carrying Value | $1.5M |
| Cash And Short Term Investments | $1.5M |
| Inventory | $113K |
| Current Net Receivables | $5M |
| Total Non Current Assets | $2.8M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $1.5M |
| Intangible Assets Excluding Goodwill | $1.5M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $1.3M |
| Short Term Investments | $517K |
| Other Current Assets | $370K |
| Other Non Current Assets | - |
| Total Liabilities | $1.4M |
| Total Current Liabilities | $1.4M |
| Current Accounts Payable | $816K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $37K |
| Total Non Current Liabilities | $9K |
| Capital Lease Obligations | $46K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $46K |
| Other Current Liabilities | $546K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $8.2M |
| Treasury Stock | - |
| Retained Earnings | -$75M |
| Common Stock | $71M |
| Common Stock Shares Outstanding | $5.8M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$5.1M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $482K |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | $629K |
| Profit Loss | - |
| Cashflow From Investment | -$1.6M |
| Cashflow From Financing | $6.2M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $0 |
| Dividend Payout Common Stock | $0 |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$7.5M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $506K |
| Total Revenue | $1.3M |
| Cost Of Revenue | $800K |
| Costof Goods And Services Sold | $800K |
| Operating Income | -$7.3M |
| Selling General And Administrative | $4.3M |
| Research And Development | $1.8M |
| Operating Expenses | $7.8M |
| Investment Income Net | - |
| Net Interest Income | $391K |
| Interest Income | $421K |
| Interest Expense | $30K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $482K |
| Income Before Tax | -$7.5M |
| Income Tax Expense | -$14K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$7.5M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$7.5M |
| Ebitda | -$7M |
| Net Income | -$6.3M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Scisparc Ltd. is an innovative clinical-stage pharmaceutical company based in Tel Aviv, Israel, focused on the research and development of cannabinoid-based therapies. With a commitment to advancing medical science, Scisparc is dedicated to creating novel treatments that leverage the therapeutic potential of cannabinoids to address a variety of medical conditions. The company aims to improve patient outcomes through its cutting-edge drug development programs, positioning itself at the forefront of the evolving cannabinoid pharmaceutical landscape.